

Diarrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/DB818EF29427EN.html>

Date: March 2022

Pages: 113

Price: US\$ 2,000.00 (Single User License)

ID: DB818EF29427EN

Abstracts

Diarrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diarrhea - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Diarrhea (Gastrointestinal) pipeline landscape.

Diarrhea is a contagious gastrointestinal infection occurring mostly due to unhygienic conditions. Diarrhea may be related to a viral or bacterial infection and is sometimes the result of food poisoning. Symptoms include nausea, abdominal pain, cramping, bloating, dehydration, fever, bloody stools, frequent urge to evacuate the bowels and incontinence. Treatment includes medication and healthy lifestyle.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diarrhea - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press

releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 11, 6, 1, 18 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 3 and 5 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Diarrhea (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Diarrhea (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Diarrhea

(Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Diarrhea (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Diarrhea (Gastrointestinal)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Diarrhea (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Diarrhea (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Diarrhea - Overview
- Diarrhea - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Diarrhea - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Diarrhea - Companies Involved in Therapeutics Development
- AbbVie Inc
- Boston Pharmaceuticals Inc
- Chongqing Zhifei Biological Products Co Ltd
- Cosmo Pharmaceuticals NV
- DiscoveryBiomed Inc
- Emergent BioSolutions Inc
- First Wave BioPharma Inc
- Glycosyn LLC
- Hilleman Laboratories Pvt Ltd
- Immuron Ltd
- Jaguar Health Inc
- Lumen Bioscience Inc
- Microba Life Sciences Ltd
- MyBiotics Pharma Ltd
- Napo Pharmaceuticals Inc
- NGM Biopharmaceuticals Inc
- Nippon Shinyaku Co Ltd
- Nuvara Therapeutics LLC
- OnQuality Pharmaceuticals LLC
- Orphomed Inc
- Prokarium Ltd
- Protagonist Therapeutics Inc

RaQualia Pharma Inc
Rebiotix Inc
RedHill Biopharma Ltd
RxBio Inc
Scandinavian Biopharma Holding AB
Synthetic Biologics Inc
Syntiron LLC
TenNor Therapeutics Ltd
Vanda Pharmaceuticals Inc
Vanessa Biotech
Wuhan Institute of Biological Products Co Ltd
Yisheng Biopharma Co Ltd
Zhiyi Pharmaceuticals Inc
Diarrhea - Drug Profiles
(Haemophilus influenzae type b + rotavirus) vaccine - Drug Profile
Product Description
Mechanism Of Action
aldafermin - Drug Profile
Product Description
Mechanism Of Action
History of Events
Antibody for Campylobacteriosis and Infectious Diarrhea - Drug Profile
Product Description
Mechanism Of Action
History of Events
AZX-1101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Biologic for Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile
Product Description
Mechanism Of Action
History of Events
BOS-589 - Drug Profile
Product Description
Mechanism Of Action

History of Events

BPO-27 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile

Product Description

Mechanism Of Action

crofelemer DR - Drug Profile

Product Description

Mechanism Of Action

History of Events

CVD-1208S122 - Drug Profile

Product Description

Mechanism Of Action

diarrhea vaccine - Drug Profile

Product Description

Mechanism Of Action

diarrhea vaccine - Drug Profile

Product Description

Mechanism Of Action

Escherichia coli vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

ETEC vaccine - Drug Profile

Product Description

Mechanism Of Action

ETEC vaccine - Drug Profile

Product Description

Mechanism Of Action

Etvax - Drug Profile

Product Description

Mechanism Of Action

History of Events

FW-420 - Drug Profile

Product Description

Mechanism Of Action

History of Events

IMM-124E - Drug Profile

Product Description

Mechanism Of Action

History of Events

IMSUTMR-1501 - Drug Profile

Product Description

Mechanism Of Action

History of Events

infectious diarrhea [serotype H11] vaccine - Drug Profile

Product Description

Mechanism Of Action

iOHW0-32 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Lechlemer - Drug Profile

Product Description

Mechanism Of Action

History of Events

LMN-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MBXMC-101 - Drug Profile

Product Description

Mechanism Of Action

ondansetron hydrochloride CR - Drug Profile

Product Description

Mechanism Of Action

History of Events

OQL-041 - Drug Profile

Product Description

Mechanism Of Action

OQL-061 - Drug Profile

Product Description

Mechanism Of Action

ORP-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Peptide to Activate NHE-3 for Diarrhea - Drug Profile

Product Description

Mechanism Of Action

prulifloxacin - Drug Profile

Product Description

Mechanism Of Action

History of Events

RBX-2660 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ribaxamase - Drug Profile

Product Description

Mechanism Of Action

History of Events

rifamycin sodium CR - Drug Profile

Product Description

Mechanism Of Action

History of Events

rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

RQ-00310941 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Rx-100 - Drug Profile

Product Description

Mechanism Of Action

History of Events

shigella [serotype 2a] vaccine - Drug Profile

Product Description

Mechanism Of Action

Shylicine - Drug Profile

Product Description

Mechanism Of Action

SK-08 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Secretory Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile

Product Description

Mechanism Of Action

History of Events

SYN-006 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SYN-007 - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides to Agonize DOR1 and MOR1 for Irritable Bowel Syndrome with Diarrhea - Drug Profile

Product Description

Mechanism Of Action

TNP-2092 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Typhetec - Drug Profile

Product Description

Mechanism Of Action

Vaccine for Traveler's Diarrhea - Drug Profile

Product Description

Mechanism Of Action

Vaccine for Traveler's Diarrhea - Drug Profile

Product Description

Mechanism Of Action

VS-002 - Drug Profile

Product Description

Mechanism Of Action

VS-014 - Drug Profile

Product Description

Mechanism Of Action

Diarrhea - Dormant Projects

Diarrhea - Discontinued Products

Diarrhea - Product Development Milestones

Featured News & Press Releases

Feb 15, 2022: Jaguar Health announces receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency

Feb 01, 2022: Jaguar health announces completion of third-party, investigator-initiated study of crofelemer, which is expected to support orphan drug designation (ODD) for crofelemer for congenital diarrheal disorders (CDD)

Jan 13, 2022: Immuron receives European patent on drug composition to treat Travelers' Diarrhea

Jan 12, 2022: Immuron awarded AU \$6.2 million to clinically evaluate a military strength dosing regimen for Travelan

Jan 04, 2022: OrphoMed announces positive phase 2 results for ORP-101 100 mg once-daily dose in IBS-D patients

Nov 16, 2021: One hundredth patient enrolled in clinical trial of world's first 2-in-1 anti-diarrheal/oral rehydration solution

Nov 10, 2021: Immuron: US DoD Naval Medical Research Center clinical update

Oct 19, 2021: Vanessa Biotech receives approval from Ghana FDA to proceed with Cholera Phase II Clinical Trial

Aug 17, 2021: Jaguar Health subsidiary announces completion of additional preclinical study of Lechlemer (NP-300), the company's human drug product candidate for diarrhea relief from cholera and other acute infectious diarrhea

Jun 25, 2021: Vanessa Biotech registers VR-AD-1005, a novel antidiarrheal investigational drug, for phase II clinical trial with the Pan African Clinical Trials Registry for treatment of severe diarrhea of cholera

Jun 01, 2021: Napo, Jaguar Health's Italian subsidiary, provides updates on plans to pursue conditional marketing authorization in the EU

May 21, 2021: RedHill Biopharma presents a new travelers' diarrhea clinical severity classification tool and its use in Aemcolo efficacy analysis at DDW 2021

Apr 16, 2021: Jaguar Health announces upsizing of At-the-Market (ATM) Financing Program by \$15.3 million with Ladenburg Thalmann & Co for potential future financing needs

Mar 22, 2021: FDA grants Orphan Drug Designation for Shylicine

Mar 01, 2021: The first children have been vaccinated in Scandinavian Biopharma's large phase IIb study in The Gambia

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Diarrhea, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Diarrhea - Pipeline by AbbVie Inc, 2022
Diarrhea - Pipeline by Boston Pharmaceuticals Inc, 2022
Diarrhea - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
Diarrhea - Pipeline by Cosmo Pharmaceuticals NV, 2022
Diarrhea - Pipeline by DiscoveryBiomed Inc, 2022
Diarrhea - Pipeline by Emergent BioSolutions Inc, 2022
Diarrhea - Pipeline by First Wave BioPharma Inc, 2022
Diarrhea - Pipeline by Glycosyn LLC, 2022
Diarrhea - Pipeline by Hilleman Laboratories Pvt Ltd, 2022
Diarrhea - Pipeline by Immuron Ltd, 2022
Diarrhea - Pipeline by Jaguar Health Inc, 2022
Diarrhea - Pipeline by Lumen Bioscience Inc, 2022
Diarrhea - Pipeline by Microba Life Sciences Ltd, 2022
Diarrhea - Pipeline by MyBiotics Pharma Ltd, 2022
Diarrhea - Pipeline by Napo Pharmaceuticals Inc, 2022
Diarrhea - Pipeline by NGM Biopharmaceuticals Inc, 2022
Diarrhea - Pipeline by Nippon Shinyaku Co Ltd, 2022
Diarrhea - Pipeline by Nuvara Therapeutics LLC, 2022
Diarrhea - Pipeline by OnQuality Pharmaceuticals LLC, 2022
Diarrhea - Pipeline by Orphomed Inc, 2022
Diarrhea - Pipeline by Prokarium Ltd, 2022
Diarrhea - Pipeline by Protagonist Therapeutics Inc, 2022
Diarrhea - Pipeline by RaQualia Pharma Inc, 2022

Diarrhea - Pipeline by Rebiotix Inc, 2022
Diarrhea - Pipeline by RedHill Biopharma Ltd, 2022
Diarrhea - Pipeline by RxBio Inc, 2022
Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, 2022
Diarrhea - Pipeline by Synthetic Biologics Inc, 2022
Diarrhea - Pipeline by Syntiron LLC, 2022
Diarrhea - Pipeline by TenNor Therapeutics Ltd, 2022
Diarrhea - Pipeline by Vanda Pharmaceuticals Inc, 2022
Diarrhea - Pipeline by Vanessa Biotech, 2022
Diarrhea - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2022
Diarrhea - Pipeline by Yisheng Biopharma Co Ltd, 2022
Diarrhea - Pipeline by Zhiyi Pharmaceuticals Inc, 2022
Diarrhea - Dormant Projects, 2022
Diarrhea - Dormant Projects, 2022 (Contd..1)
Diarrhea - Dormant Projects, 2022 (Contd..2)
Diarrhea - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Diarrhea, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Diarrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/DB818EF29427EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DB818EF29427EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

